Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry

Abstract Aims Hypertensive disorders of pregnancy (HDP) occur in 10% of pregnancies in the general population, pre-eclampsia specifically in 3–5%. Hypertensive disorders of pregnancy may have a high prevalence in, and be poorly tolerated by, women with heart disease. Methods and results The prevalence and outcomes of HDP (chronic hypertension, gestational hypertension or pre-eclampsia) were assessed in the ESC EORP ROPAC (n = 5739), a worldwide prospective registry of pregnancies in women with heart disease. The overall prevalence of HDP was 10.3%, made up of chronic hypertension (5.9%), gestational hypertension (1.3%), and pre-eclampsia (3%), with significant differences between the types of underlying heart disease (P < 0.05). Pre-eclampsia rates were highest in women with pulmonary arterial hypertension (PAH) (11.1%), cardiomyopathy (CMP) (7.1%), and ischaemic heart disease (IHD) (6.3%). Maternal mortality was 1.4 and 0.6% in women with vs. without HDP (P = 0.04), and even 3.5% in those with pre-eclampsia. All pre-eclampsia-related deaths were post-partum and 50% were due to heart failure. Heart failure occurred in 18.5 vs. 10.6% of women with vs. without HDP (P < 0.001) and in 29.1% of those with pre-eclampsia. Perinatal mortality was 3.1 vs. 1.7% in women with vs. without HDP (P = 0.019) and 4.7% in those with pre-eclampsia. Conclusion Hypertensive disorders of pregnancy and pre-eclampsia rates were higher in women with CMP, IHD, and PAH than in the general population. Adverse outcomes were increased in women with HDP, and maternal mortality was strikingly high in women with pre-eclampsia. The combination of HDP and heart disease should prompt close surveillance in a multidisciplinary context and the diagnosis of pre-eclampsia requires hospital admission and continued monitoring during the post-partum period.

[1]  Joshua I. Rosenbloom,et al.  Preeclampsia Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction. , 2021, Journal of the American College of Cardiology.

[2]  W. Gyselaers,et al.  Preeclampsia has two phenotypes which require different treatment strategies. , 2021, American journal of obstetrics and gynecology.

[3]  F. Figueras,et al.  Incidence of pre‐eclampsia and other perinatal complications among pregnant women with congenital heart disease: systematic review and meta‐analysis , 2020, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[4]  K. Sliwa,et al.  Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). , 2019, European heart journal.

[5]  N. Marlow,et al.  Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial , 2019, The Lancet.

[6]  J. Illuzzi,et al.  Severe cardiovascular morbidity in women with hypertensive diseases during delivery hospitalization. , 2019, American journal of obstetrics and gynecology.

[7]  S. Karumanchi,et al.  Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .

[8]  Erkan Kalafat,et al.  Cardiovascular System in Preeclampsia and Beyond , 2019, Hypertension.

[9]  ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. , 2019, Obstetrics and gynecology.

[10]  B. Mulder,et al.  Maternal right ventricular function, uteroplacental circulation in first trimester and pregnancy outcome in women with congenital heart disease , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[11]  R. Chettier,et al.  Cardiomyopathy and Preeclampsia: Shared Genetics? , 2018, Circulation.

[12]  M. Metra,et al.  Pre‐eclampsia and heart failure: a close relationship , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[13]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[14]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[15]  L. Magee,et al.  Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. , 2018, Hypertension.

[16]  K. Nicolaides,et al.  Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis , 2017, American journal of obstetrics and gynecology.

[17]  E. Foster,et al.  Maternal and Fetal Outcomes of Admission for Delivery in Women With Congenital Heart Disease , 2017, JAMA cardiology.

[18]  K. Sliwa,et al.  Imbalanced Angiogenesis in Peripartum Cardiomyopathy - Diagnostic Value of Placenta Growth Factor. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[19]  K. Stergiopoulos,et al.  National Trends and In-Hospital Outcomes in Pregnant Women With Heart Disease in the United States. , 2017, The American journal of cardiology.

[20]  A. Rosengren,et al.  Heart Failure in Late Pregnancy and Postpartum: Incidence and Long-Term Mortality in Sweden From 1997 to 2010. , 2017, Journal of cardiac failure.

[21]  Erkan Kalafat,et al.  Cardiovascular origins of preeclampsia , 2017, Current opinion in obstetrics & gynecology.

[22]  R. Platt,et al.  Secular Trends in Preeclampsia Incidence and Outcomes in a Large Canada Database: A Longitudinal Study Over 24 Years. , 2016, Canadian Journal of Cardiology.

[23]  N. Marx,et al.  Autoantibodies in dilated cardiomyopathy induce vascular endothelial growth factor expression in cardiomyocytes. , 2015, Biochemical and biophysical research communications.

[24]  Y. Kamisah,et al.  The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). , 2015, Vascular pharmacology.

[25]  Roman Goldenberg,et al.  Reducing maternal mortality from preeclampsia and eclampsia in low‐resource countries – what should work? , 2015, Acta obstetricia et gynecologica Scandinavica.

[26]  B. Mulder,et al.  Uteroplacental Blood Flow, Cardiac Function, and Pregnancy Outcome in Women With Congenital Heart Disease , 2013, Circulation.

[27]  K. Joseph,et al.  Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. , 2013, American journal of obstetrics and gynecology.

[28]  R. Hall,et al.  Heart failure in pregnant women with cardiac disease: data from the ROPAC , 2013, Heart.

[29]  R. Hall,et al.  Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. , 2013, European heart journal.

[30]  K. Joseph,et al.  Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[31]  B. Mulder,et al.  Outcome of pregnancy in women with congenital heart disease: a literature review. , 2007, Journal of the American College of Cardiology.

[32]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[33]  C. Berg,et al.  Pregnancy‐Related Mortality From Preeclampsia and Eclampsia , 2001, Obstetrics and gynecology.